Assessing Sihuan Pharmaceutical Holdings Group’s Valuation After Bireociclib’s New First Line Breast Cancer Approval

Simply Wall St.

Mar 11

Sihuan Pharmaceutical Holdings Group (SEHK:460) drew investor attention after China approved a new first-line indication for its Bireociclib Tablets in HR+/HER2- advanced breast cancer, expanding ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2618793945"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618793945\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618793945?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-03-11 16:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618793945","market":"sg","top_or_hot":-1,"title":"Assessing Sihuan Pharmaceutical Holdings Group’s Valuation After Bireociclib’s New First Line Breast Cancer Approval","media":"Simply Wall St.","content":"<div>\n<p>Sihuan Pharmaceutical Holdings Group (SEHK:460) drew investor attention after China approved a new first-line indication for its Bireociclib Tablets in HR+/HER2- advanced breast cancer, expanding ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/assessing-sihuan-pharmaceutical-holdings-groups-valuation-af\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Sihuan Pharmaceutical Holdings Group’s Valuation After Bireociclib’s New First Line Breast Cancer Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Sihuan Pharmaceutical Holdings Group’s Valuation After Bireociclib’s New First Line Breast Cancer Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-11 16:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/assessing-sihuan-pharmaceutical-holdings-groups-valuation-af><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sihuan Pharmaceutical Holdings Group (SEHK:460) drew investor attention after China approved a new first-line indication for its Bireociclib Tablets in HR+/HER2- advanced breast cancer, expanding ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/assessing-sihuan-pharmaceutical-holdings-groups-valuation-af\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/assessing-sihuan-pharmaceutical-holdings-groups-valuation-af","article_id":"2618793945","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/assessing-sihuan-pharmaceutical-holdings-groups-valuation-af","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618793945","pubTimestamp":1773218361,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sihuan Pharmaceutical Holdings Group (SEHK:460) drew investor attention after China approved a new first-line indication for its Bireociclib Tablets in HR+/HER2- advanced breast cancer, expanding coverage across all treatment lines.\nSee our latest analysis for Sihuan Pharmaceutical Holdings Group.\nAt a share price of HK$1.49, the stock has seen a 6.43% 7 day share price return and a 16.41% 90 day share price return. The 1 year total shareholder return of 150.06% points to strong momentum,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK1593":"医美概念股","BK1600":"工业大麻","00460":"四环医药"},"translate_title":"评估Bireociclib新一线乳腺癌获批后四环医药控股集团的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":0.9,"DCF":1},"content_text":"Sihuan Pharmaceutical Holdings Group (SEHK:460) drew investor attention after China approved a new first-line indication for its Bireociclib Tablets in HR+/HER2- advanced breast cancer, expanding coverage across all treatment lines. See our latest analysis for Sihuan Pharmaceutical Holdings Group. At a share price of HK$1.49, the stock has seen a 6.43% 7 day share price return and a 16.41% 90 day share price return. The 1 year total shareholder return of 150.06% points to strong momentum, which contrasts with a 1 month share price return of 9.15%. If this regulatory win has you looking beyond a single name, it could be a good time to check out 116 healthcare AI stocks as another way to spot potential opportunities in healthcare and related technologies. With Bireociclib now covering all treatment lines and the shares already delivering a 150% 1 year total return, the real question is whether Sihuan is still undervalued or if the market has already priced in future growth. AdvertisementPrice-to-Sales of 5.7x: Is it justified? On a P/S of 5.7x at a HK$1.49 share price, Sihuan trades at a richer level than many Hong Kong pharma peers, even though it is currently loss making. The P/S ratio compares a company’s market value to its revenue. It is often used for businesses where earnings are still volatile or negative, like Sihuan. Here, investors are effectively paying 5.7 times the company’s annual sales. This level indicates that the market is placing a premium on its revenue base and future potential. That premium stands out when compared with the Hong Kong Pharmaceuticals industry average P/S of 2.9x and a peer average of 11.5x. Sihuan’s multiple is above the broader industry but below closer peers. The estimated fair P/S of 8.9x indicates that this ratio is being assessed against a higher reference point. Explore the SWS fair ratio for Sihuan Pharmaceutical Holdings Group Result: Price-to-Sales of 5.7x (ABOUT RIGHT) However, there are clear watchpoints, including the current net loss of CN¥80.635m and the recent 9.15% one-month share price decline, that could challenge sentiment. Find out about the key risks to this Sihuan Pharmaceutical Holdings Group narrative. Another View: DCF Flags a Very Different Story While the 5.7x P/S suggests Sihuan is cheaper than peers on sales, our DCF model points the other way. At HK$1.49, the shares sit well above an estimated future cash flow value of HK$0.11. This implies the price is rich if those cash flow assumptions play out. That is a sharp gap for anyone leaning on cash flow based valuation. The key question is whether you trust the revenue and earnings outlook enough to justify paying so far above that DCF mark. Look into how the SWS DCF model arrives at its fair value. 460 Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sihuan Pharmaceutical Holdings Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 220 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps The mix of upbeat returns and valuation questions makes this a stock that splits opinion, so move quickly to review the data yourself and decide where you stand by starting with 1 key reward. Ready for more investment ideas? If this story has you thinking bigger about your portfolio, do not stop here. Use the screener to quickly surface ideas that fit your style and risk comfort.  Target potential value opportunities by scanning our 220 high quality undervalued stocks that combine quality fundamentals with what may be attractive pricing. Strengthen your income corner by reviewing 459 dividend fortresses that focus on higher yielding companies with an eye on stability. Prioritise resilience by checking out 305 resilient stocks with low risk scores designed to highlight businesses with lower overall risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}